Recruiting
Phase 1
Phase 2

ADI-270

Sponsor:

Adicet Therapeutics

Code:

NCT06480565

Conditions

Clear Cell Renal Cell Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ADI-270

Fludarabine

Cyclophosphamide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-19. This information was provided to ClinicalTrials.gov by Adicet Therapeutics on 2024-11-22.